Author: admin

  • Luis Suarez, Steven Lenhart receive additional suspension from MLS for Leagues Cup melee

    Luis Suarez, Steven Lenhart receive additional suspension from MLS for Leagues Cup melee

    MLS have handed out additional suspensions to Inter Miami CF forward Luis Suárez and Seattle Sounders assistant Steven Lenhart for their roles in an altercation following the Sounders’ victory in the Leagues Cup final.

    Suarez has been suspended for three games, while Lenhart has had his credential revoked for the rest of the 2025 season, including the playoffs. Additionally, the Sounders were fined for misappropriation of credentials.

    Miami midfielder Sergio Busquets and defender Tomas Aviles were not given additional suspensions by MLS. The Leagues Cup Organizing Committee suspended Busquets (two games) and Aviles (three games), but that punishment only applies to that competition.

    Lenhart — best known for his playing days with the San Jose Earthquakes with his physical style of play — joined the Sounders coaching staff to work with players on the mental side of the game.

    In the below video, Lenhart is the Sounders staffer in the white hat throwing punches.

    The Leagues Cup suspensions for Suarez (six games) and Lenhart (five games) still stand, which will begin next year when the competition returns. It remains an open question if Suarez will continue playing at all in 2026 or if he’ll retire. Ditto for Busquets.

    Seattle beat Miami 3-0 to lift the Leagues Cup trophy on August 31 and, after the final whistle, Miami sparked a coming together between the sides in which punches were thrown, Suarez spit on Sounders security director Gene Ramirez and Busquets put his hand on Obed Vargas’ face to help ignite the fracas. Miami hosts Seattle on Tuesday, September 16, a must-watch match following the Leagues Cup melee.

    Suarez will miss matches against Charlotte, Seattle and D.C. United. Miami sit sixth in the Eastern Conference but have four games in hand over most of the teams above them. If they were to win all four games in hand, they would be first in MLS.

    Seattle, fresh off winning the Leagues Cup, are one of the top title contenders heading towards the playoffs.

    Continue Reading

  • Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases

    Dato-DXd Leads to Intracranial Responses in Advanced/Metastatic NSCLC With Brain Metastases

    Advanced NSCLC | Image by Ashling Wahner

    & MJH Life Sciences Using AI

    Datopotamab deruxtecan-dlnk (Dato-DXd; Datroway) displayed intracranial activity in patients with advanced or metastatic non–small cell lung cancer (NSCLC) with brain metastases, according to data from a post hoc analysis of the phase 3 TROPION-Lung01 study (NCT04656652) presented during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer.1

    At the August 30, 2024, data cutoff, findings from the study demonstrated that patients who received Dato-DXd (n = 38) experienced a median central nervous system (CNS) progression-free survival (PFS) of 5.0 months (95% CI, 3.5-not estimable [NE]) compared with 3.0 months (95% CI, 1.3-6.6) among those who received docetaxel (n = 30; unstratified HR, 0.48; 95% CI, 0.23-0.98). The 3-month CNS PFS rates were 77% and 48%, respectively, and the 6-month CNS PFS rates were 41% and 29%, respectively.

    “In this post-hoc analysis of TROPION-Lung01, intracranial response and PFS showed numerical improvement vs docetaxel,” Elvire Pons-Tostivint, MD, PhD, of the Department of Medical Oncology at the University Hospital of Nantes in France, wrote in the presentation. “Dato-DXd demonstrated intracranial activity in patients with advanced or metastatic NSCLC and brain metastases, consistent with previous studies of DXd antibody-drug conjugates in multiple solid tumors.”

    In June 2025, Dato-DXd was granted accelerated approval by the FDA for the treatment of adult patients with locally advanced EGFR-mutated NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy.2 The regulatory decision was supported by prior data from TROPION-Lung01 and the phase 2 TROPION-Lung05 trial (NCT04484142).

    What Were the Key Design and Baseline Patient Characteristics of TROPION-Lung01?

    TROPION-Lung01 was an open-label study that enrolled patients with stage IIIB, IIIC, or IV NSCLC.1 Eligible patients also needed to have an ECOG performance status of 0 or 1 and have not received prior docetaxel. Those with clinically inactive, asymptomatic brain metastases were eligible for enrollment.

    Patients without actionable genomic alterations needed to have received 1 to 2 prior lines of therapy, including platinum-based chemotherapy and an anti–PD-(L)1 monoclonal antibody. Those with actionable genomic alterations, consisting of EGFR, ALK, NTRK, BRAF, ROS1, MET exon 14 skipping, and/or RET alterations, needed to have received 1 to 2 prior approved targeted therapies, platinum-based chemotherapy, and at least 1 anti–PD-(L)1 monoclonal antibody.

    Patients were randomly assigned 1:1 to receive Dato-DXd at 6 mg/kg every 3 weeks or docetaxel at 75 mg/m2 every 3 weeks. Stratification occurred based on disease histology, actionable genomic alterations, the inclusion of an anti–PD-(L)1 monoclonal antibody in the most recent prior therapy, and region.

    The dual primary end points were PFS by blinded independent review committee (BICR) per RECIST 1.1 criteria and overall survival (OS). CNS overall response rate (ORR), disease control rate (DCR), and PFS by CNS BICR per CNS RECIST criteria, as well as percentage change from baseline in the sum of diameters in measurable brain metastases, were also assessed in the post-hoc analysis.

    At baseline, patients in the Dato-DXd and docetaxel arms were a median age of 65.5 years (range, 35-81) and 57.5 years (range, 34-77), respectively. Most patients in both arms had an ECOG performance status of 1 (71% vs 63%), nonsquamous histology (82% vs 83%), and did not have actionable genomic alterations (68% vs 60%). The median times from diagnosis to random assignment were 14.4 months (range, 3.0-87.0) and 20.6 months (range, 3.4-73.1), respectively.

    What Were the Additional CNS Efficacy Data from the TROPION-Lung01 Study?

    Additional findings from the post hoc analysis revealed that patients with untreated brain metastases or disease progression after radiotherapy with CNS measurable disease who received Dato-DXd (n = 16) achieved a CNS confirmed ORR of 38% (95% CI, 15%-65%) and a CNS confirmed DCR of 88% (95% CI, 62%-98%). The CNS confirmed complete response (CR), partial response (PR), and stable disease rates were 6%, 31%, and 50%, respectively.

    In the docetaxel arm (n = 11), the CNS confirmed ORR was 0% (95% CI, 0%-29%), and the CNS confirmed DCR was 36% (95% CI, 11%-69%). No patients achieved a CNS CR or PR, and 36% experienced CNS stable disease.

    There was a benefit in terms of CNS PFS in favor of the Dato-DXd arm among patients with nonsquamous histology (n = 56; HR, 0.37; 95% CI, 0.16-0.83), EGFR-unmutated disease (n = 46; HR, 0.51; 95% CI, 0.21-1.27), and EGFR-mutated disease (n = 22; HR, 0.33; 95% CI, 0.09-1.20). Patients with squamous histology (n = 12) did not experience a CNS PFS benefit with Dato-DXd (HR, 1.81; 95% CI, 0.30-11.02).

    “Limitations [of this post-hoc analysis] include small numbers in some subgroups, high censoring due to missing CNS imaging, and on-treatment scans only [being] required for patients with baseline brain metastases,” Pons-Tostivint and her coauthors wrote in conclusion.

    References

    1. Pons-Tostivint E, Okamoto I, Ahn MJ, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with advanced/metastatic NSCLC in TROPION-Lung01. Presented at: International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer; September 6-9, 2025; Barcelona, Spain. Abstract OA10.01.
    2. FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer. FDA. June 23, 2025. Accessed September 8, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-datopotamab-deruxtecan-dlnk-egfr-mutated-non-small-cell-lung-cancer

    Continue Reading

  • Full Phase 3 Results Indicate Reduced Blood Pressure With Baxdrostat in Hypertension

    Full Phase 3 Results Indicate Reduced Blood Pressure With Baxdrostat in Hypertension

    At the European Society of Cardiology (ESC) Congress 2025, investigators from AstraZeneca presented full trial results from the phase 3 BaxHTN trial, demonstrating that baxdrostat induced statistically meaningful and clinically significant reductions in mean seated systolic blood pressure (SBP) at either 1- or 2-mg doses compared with placebo at 12 weeks in patients with uncontrolled or resistant hypertension receiving standard of care. The results, which were first announced in July 2025 with the release of top-line data, were also published in The New England Journal of Medicine and announced in a news release from AstraZeneca.1,2

    Hypertension is a major contributor to adverse cardiovascular outcomes. | Image Credit: ©interstid – stock.adobe.com

    Baxdrostat, an investigational, highly selective, oral small molecule drug, inhibits aldosterone synthase, a major contributor to hypertension through promotion of sodium and water retention. Elevated aldosterone levels in the body can make elevated blood pressure complicated to treat and heighten the risk of adverse cardiovascular events, including heart attack. With the potential to act as a first-in-class and potent treatment option, baxdrostat offers numerous advantages compared with the standard of care. Most pertinently, it can lower aldosterone levels without impacting cortisol, a hormone in the adrenal glands that helps regulate stress responses in the body.1-3

    Full BaxHTN Data Demonstrates Major Blood Pressure Reductions

    According to the full BaxHTN results, baxdrostat met all primary and secondary end points in the trial. There was a significant reduction from baseline in mean seated SBP—15.7 mmHg—at week 12 (95% CI, –17.6 to –13.7), whereas the placebo-adjusted reduction was 9.8 mmHg (95% CI, –12.6 to –7.0; P < .001) for patients treated with the 2-mg dose of baxdrostat. For those administered the 1-mg dose, the absolute reduction from baseline was 14.5 mmHg (95% CI, –16.5 to –12.5), and the placebo-adjusted reduction was 8.7 mmHg (95% CI, –11.5 to –5.8; P < .001).1

    Compared with the reduction in mean seated SBP with placebo (5.8 mmHg [95% CI, –7.9 to –3.8]), both doses of baxdrostat were significantly more effective at reducing SBP. Importantly, these results were consistent in both treatment-resistant and uncontrolled subgroups of hypertension, the investigators reported.1

    Confirmatory secondary end points with baxdrostat were also successfully met. These end points included demonstration of durable long-term blood pressure reductions with a 2-mg baxdrostat dose. Furthermore, each dose of baxdrostat induced significant reductions in diastolic blood pressure while nearly tripling the odds of patients reaching a target SBP of less than 130 mmHg compared with placebo.1

    A prespecified exploratory analysis in a subgroup of patients was conducted to investigate reductions in ambulatory nighttime SBP compared with placebo. According to this analysis, baxdrostat was found to meaningfully reduce 24-hour and ambulatory nighttime SBP­­—the 2-mg dose lowered 24-hour SBP by 16.9 mmHg (95% CI, –25.6 to –8.3), while the pooled 2-mg and 1-mg doses reduced nighttime SBP by 11.7 mmHg (95% CI, –19.5 to -3.8). More research is necessary to better elucidate the impacts of baxdrostat on nighttime SBP; in this regard, the phase 3 Bax24 trial, which is set to evaluate 24-hour ambulatory effects of baxdrostat on SBP, is expected to have results available by the end of 2025.1

    “Achieving a nearly 10 mmHg placebo-adjusted reduction in systolic blood pressure with baxdrostat in the BaxHTN phase 3 trial is exciting, as this level of reduction is linked to substantially lower risk of heart attack, stroke, heart failure, and kidney disease,” primary study investigator Bryan Williams, MD, chair of medicine at University College London, said in the news release regarding the trial’s efficacy data. “These data show that aldosterone plays a greater role in hard-to-control hypertension than previously recognized, underscoring the importance of baxdrostat’s novel mechanism of action and potential impact for the millions of people living with hard-to-control hypertension despite being on multiple treatments.”1

    Safety of Baxdrostat and Implications for Patients

    In critical findings, baxdrostat was well-tolerated among the patient population, and there were no unanticipated safety indications, according to the study researchers. As for any observed adverse events (AEs), there were low rates of confirmed hyperkalemia (> 6 mmol/L) in both dose groups compared with placebo. Hyperkalemia is characterized by abnormally high levels of potassium in the blood; with symptoms including abdominal pain and diarrhea, pharmacists will be integral in monitoring patients taking baxdrostat for these possible complications.1,4

    Despite the appearance of hyperkalemia, the safety profile of baxdrostat was consistent with its mechanism of action, and most instances of AEs were mild. Based on these observations, baxdrostat stands to present as a safe, novel option for reducing SBP in patients with uncontrolled hypertension if approved in the future.1

    Millions of individuals in the United States live with hypertension, and about half of those who utilize multiple therapies remain harboring uncontrolled blood pressure. Baxdrostat has the potential to transform the treatment paradigm for uncontrolled or resistant hypertension and could provide relief to individuals utilizing a series of different drugs to control their hypertension. Pharmacists will play an essential role in counseling patients on baxdrostat’s use and dosage if the drug is eventually approved by the FDA.1,5

    “The BaxHTN phase 3 results demonstrate baxdrostat’s potential in tackling one of the toughest challenges in cardiovascular care, which is hypertension that is hard to control despite multiple therapies.”1

    REFERENCES
    1. Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III trial. AstraZeneca. News Release. Released August 30, 2025. Accessed September 8, 2025. https://www.astrazeneca-us.com/media/press-releases/2025/Baxdrostat-demonstrated-statistically-significant-and-clinically-meaningful-reduction-in-systolic-blood-pressure-in-patients-with-hard-to-control-hypertension-in-the-BaxHTN-Phase-III-trial.html
    2. Halpern L. Baxdrostat Reduces Systolic Blood Pressure in Uncontrolled, Treatment-Resistant Hypertension. Pharmacy Times. Published July 31, 2025. Accessed September 8, 2025. https://www.pharmacytimes.com/view/baxdrostat-reduces-systolic-blood-pressure-in-uncontrolled-treatment-resistant-hypertension
    3. Cleveland Clinic. Cortisol. Last Updated February 17, 2025. Accessed September 8, 2025. https://my.clevelandclinic.org/health/articles/22187-cortisol
    4. Cleveland Clinic. Hyperkalemia (High potassium). Last Updated May 11, 2023. Accessed September 8, 2025. https://my.clevelandclinic.org/health/diseases/15184-hyperkalemia-high-blood-potassium#symptoms-and-causes
    5. Carey RM, Sakhuja S, Calhoun DA, et al. Prevalence of Apparent Treatment-Resistant Hypertension in the United States. Hypertension. 2019;73(2):424-431. doi:10.1161/HYPERTENSIONAHA.118.12191

    Continue Reading

  • Tottenham Hotspur CEO Vinai Venkatesham insists the club is not for sale

    Tottenham Hotspur CEO Vinai Venkatesham insists the club is not for sale

    Tottenham Hotspur have moved quickly to quash takeover speculation in the wake of Daniel Levy’s shock decision to step down as chairman. CEO Vinai Venkatesham has reaffirmed that Spurs are not for sale, despite recent interest from would-be buyers.

    On Sunday night, the club and its majority owner, ENIC, issued an unambiguous statement, transcribed by Sky Sports Football: “Tottenham Hotspur is not for sale and ENIC has no intention to accept any such offer.” The announcement followed reports that two separate groups, one involving financier Amanda Staveley’s PCP International and another consortium led by Dr Roger Kennedy and Wing Fai-Ng of Triller, had expressed interest in buying the club. PCP subsequently ruled themselves out of the running.

    Advertisement

    The timing of the speculation has heightened intrigue. Levy’s exit last week ended nearly 25 years of leadership, during which, despite the relative lack of on-field success, he transformed Spurs into one of Europe’s richest clubs, moving into their state-of-the-art £1bn stadium and regularly competing in the Champions League. His departure sparked questions over whether ownership could also be in flux.

    Venkatesham, however, was unequivocal. “The Lewis family are really clear,” he said. “They see their involvement in Tottenham Hotspur being long-term, continuing through the generations. We made a statement very late on Sunday night and I hope it was unambiguously clear that Tottenham Hotspur is not for sale.”

    He also emphasised ENIC’s financial commitment to the club. “There is firm backing against our ambitions to be successful on the pitch, both on the men’s and women’s side. They know that will require investment, and we have their support to do that, of course in line with financial fair play rules.

    Despite persistent rumours of foreign interest, including previously denied links with Qatar Sports Investments, Tottenham remains among the few major English clubs not to have changed hands in the past quarter-century. With the club valued at as much as £4bn, clarity over ownership was deemed essential following Levy’s departure.

    For now, Venkatesham’s message is clear: Spurs are not on the market, and their future lies firmly in ENIC’s hands.

    GFN | Finn Entwistle

    Continue Reading

  • Keap1 Knockdown Tackles Allergic Rhinitis

    Keap1 Knockdown Tackles Allergic Rhinitis

    https://doi.org/10.1016/j.apsb.2025.05.025

    This new article publication from Acta Pharmaceutica Sinica B, discusses the efficacy of targeting the Keap1 system through the homoPROTAC-ing technology as an innovative and promising treatment strategy for the incurable allergic disorders.

    Allergic rhinitis (AR), a globally prevalent immune-mediated inflammatory condition, is still an incurable disease. The authors of this article validated the impact of the Kelch-like ECH associated protein 1 (Keap1)-related oxidative stress and inflammatory response in clinical AR patient peripheral blood and nasal swab samples, emphasizing the biological relevance of Keap1 and AR. Targeting Keap1 -nuclear factor erythroid 2-related factor 2 (Nrf2) related anti-oxidative stress may be effective for AR intervention. Drawing inspiration from the Keap1 homodimerization and the E3 ligase characteristics, a design of novel bivalent molecules for chemical knockdown of Keap1 is presented. For the first time, ternary complexes of Keap1 dimer and one molecule of bivalent compounds are characterized. The best bivalent molecule 8 encompasses robust capacity to degrade Keap1 as a homoPROTACKEAP1. It efficaciously suppresses inflammatory cytokines in extensively different cells, including human nasal epithelial cells. Moreover, in an AR mouse model, it was confirmed that the chemical degradation induced by homoPROTACKEAP1 led to therapeutic benefits in managing AR symptoms, oxidative stress and inflammation. In summary, these findings underscore the efficacy of targeting the Keap1 system through the homoPROTAC-ing technology as an innovative and promising treatment strategy for the incurable allergic disorders.

    Keywords: Allergic rhinitis, Keap1, Nrf2, E3 ligase, Degradation, HomoPROTAC

    Graphical Abstract: available at https://ars.els-cdn.com/content/image/1-s2.0-S2211383525003314-ga1_lrg.jpg

    A new divalent molecule was designed to target the Keap1 system through homoPROTAC-ing technology as an innovative and promising strategy for the treatment of AR.

    /Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.

    Continue Reading

  • Highlights from the VMAs, from Mariah Carey’s first win to Lady Gaga’s magic act

    Highlights from the VMAs, from Mariah Carey’s first win to Lady Gaga’s magic act

    Lady Gaga, Mariah Carey and Busta Rhymes were among the stars who performed — and took home awards — at Sunday night’s MTV Video Music Awards. Image: Manny Carabel (2) and Arturo Holmes/Getty Images for MTV

    Some of the biggest names in music assembled in New York Sunday night for the time-honored tradition of the MTV Video Music Awards, only this time on an even bigger stage.

    In addition to the cable channel that created it, the VMAs also aired live on CBS (and its streaming service Paramount+) for the first time in its 41-year history.

    The move seeks to expand the award show’s reach after last year’s milestone 40th anniversary broadcast, which CBS says “delivered its biggest multi-network audience in four years … and ranked as the most social VMAs in show history.”

    Notably, this year brings the VMAs — sometimes called “the Super Bowl for youth” — to the broadcast network with the oldest primetime audience.

    The show made some changes this time around, like adding two new award categories — best pop artist and best country — to spotlight rising talent while also honoring a slew of veteran stars, like Mariah Carey and Ricky Martin.

    And while the numbers aren’t in yet, this year’s VMAs certainly had their share of viral red carpet moments (see: Doja Cat taking a bite out of her lipstick), onstage performances (including Tate McRae’s impassioned dance break) and acceptance speech sound bites (like Rosé and Ariana Grande each thanking their therapists (“and gay people,” in Grande’s case).

    Here’s a look at some of the highlights.

    Mariah Carey and Busta Rhymes get their long-awaited honors

    Ariana Grande bows down to Mariah Carey as she presents her the Video Vanguard Award during the MTV VMAs on Sunday night.

    Ariana Grande bows down to Mariah Carey as she presents her the Video Vanguard Award during the MTV VMAs on Sunday night. Image: Angela Weiss/AFP via Getty Images

    Carey graced the stage in a glimmering gold bodysuit to perform a medley of her hits before Ariana Grande literally bowed down and presented her with the most prestigious award of the night: the Video Vanguard Award.

    It was Carey’s first VMA appearance in 20 years, and the first time she’s won a “Moon Person” trophy — a snub she had joked about years earlier. Despite her soon-to-be-16 studio albums and six Grammy awards, it wasn’t until Sunday that Carey won her first Moon Person trophy, when “Type Dangerous” was crowned the best R&B video during the pre-show.

    “I can’t believe I’m getting my first VMA tonight,” Carey later said while accepting the lifetime achievement award. “I just have one question: What in the Sam Hill were you waiting for?”

    As the crowd cheered, Carey clarified that she was kidding before reminiscing on some of her favorite memories from past VMAs and her vast catalogue of music videos, from playing her own stalker in Obsessed to making a romantic, James Bond-esque escape in Honey.

    “After all this time, I’ve learned that music evolves, videos evolve, but the fun — that is eternal,” she said.

    Hip-hop legend Busta Rhymes also finally got his flowers, after performing an impassioned mashup of his hit songs — including “Break Ya Neck,” “Touch It” and “Scenario” — joined by rappers Joyner Lucas, Papoose and GloRilla, all dressed in red leather ensembles.

    LL Cool J presented him with the inaugural Rock the Bells Visionary Award. It’s Rhymes’ first win, despite being nominated for 16 VMAs throughout his career.

    “Y’all know I usually do these long speeches, I’m not gonna do one today,” the rapper and record producer said in his speech. “But next time y’all take 35 years to give me one of these, y’all gonna let me talk as long as I want!”

    Rhymes went on to pay tribute to the “late, great, incredible royal empress” Ananda Lewis, the former MTV VJ who died of breast cancer earlier this year.

    “I think we all need to acknowledge the incredible woman [who] loved us when we came to MTV during the ’90s,” he said. “She loved us, she loved the culture [and] she lifted us up.”

    Sabrina Carpenter spotlights drag queens 

    Sabrina Carpenter used her VMA performance, featuring well-known drag queens, to stand up for transgender rights.

    Sabrina Carpenter used her VMA performance, featuring well-known drag queens, to stand up for transgender rights. Image: Arturo Holmes/Getty Images

    Carpenter performed the song “Tears” from her recently released album Man’s Best Friend for the first time, standing up — and dancing — for transgender rights in the process.

    She turned the stage into a slice of 1980s-era New York City: entering through a pothole, getting fake-flashed by a man in a trench coat, singing from a phone booth and pulling off a rain-drenched dance break, flanked by bare-chested police officers.

    Carpenter was joined onstage by backup dancers and a number of high-profile RuPaul’s Drag Race queens posing as well-choreographed protesters. They held up signs with slogans like “Support local drag,” “Protect trans rights” and “If you hate you’ll never get laid.”

    Later, after winning best album for 2024’s Short n’ Sweet, Carpenter thanked “my queens onstage with me tonight.”

    “This world, as we all know, can be so full of criticism and discrimination and negativity,” she said. “So to get to be part of … something that can bring you light, make you smile, make you dance, and make you feel like the world is [yours], I’m so grateful. So grateful to do that.”

    Ricky Martin makes history 

    Ricky Martin performed before receiving the show's first-ever Latin Icon Award.

    Ricky Martin performed before receiving the show’s first-ever Latin Icon Award. Image: Manny Carabel/Getty Images

    Ricky Martin also performed, descending onstage in a cage to sing “Livin’ la Vida Loca” and other hits before receiving the show’s inaugural Latin Icon Award.

    It was presented by Jessica Simpson, who opened for Martin on his Livin’ la Vida Loca tour in 1999.

    “This is for you all. Thank you so much for your applause. I am addicted to your applause, that’s why I keep coming back,” Martin said. “It’s been 40 years. I started when I was a baby, working, and we’re still here.”

    He dedicated the award to his four kids, saying, “Everything I do, I do with you in my mind and my heart.”

    A rocking tribute to Ozzy Osbourne 

    Yungblud, Steven Tyler, and Joe Perry performed a tribute to the late Ozzy Osbourne.

    Yungblud, Steven Tyler, and Joe Perry performed a tribute to the late Ozzy Osbourne. Image: Arturo Holmes/Getty Images

    Steven Tyler and Joe Perry of Aerosmith, English singer Yungblud and guitarist Nuno Bettencourt joined forces to pay tribute to Ozzy Osbourne, the Black Sabbath frontman who died in July at age 76.

    The late heavy metal icon’s son Jack introduced the act with his four kids in a pre-recorded video, saying he wished he could be there in person and that he knows it would make his dad “incredibly happy to see these great musicians carry on his legacy and help inspire the next generation of rockers.”

    “In the words of our papa — let’s go crazy!” the family members concluded in unison.

    Onstage, Yungblud sang “Crazy Train” and “Changes,” accompanied by Bettencourt. He then joined the Aerosmith members to sing “Mama, I’m Coming Home,” ending with a group hug and a cry of “Ozzy forever, man!”

    Lady Gaga’s monstrous multitasking 

    Lady Gaga was one of the night's performers, even as she put on her own concert at Madison Square Garden.

    Lady Gaga was one of the night’s performers, even as she put on her own concert at Madison Square Garden. Image: Mike Coppola/Getty Images

    Lady Gaga was the night’s most-nominated artist, with 12 nods. She won four, bringing her career total to 22 wins — the third-most behind Taylor Swift and Beyoncé.

    But perhaps even more impressive was how she managed to be in two places at once. Gaga started the night by accepting the award for artist of the year.

    “I cannot begin to tell you how much this award means to me,” she said in a visibly emotional speech, dedicating it to her fans and her fiancé.

    She concluded: “I wish I could stay and watch all these amazing performances, but I have to go back to Madison Square Garden.”

    Then she booked it out of UBS Arena in Long Island to Manhattan’s Madison Square Garden, where she was scheduled to perform at her Mayhem Ball tour in front of a sold-out crowd — despite being advertised as one of the VMAs performers.

    Lady Gaga managed the balancing act like a bona fide magician, thanks to a gorgeously grotesque pre-recorded performance of “Abracadabra” and “The Dead Dance” at Madison Square Garden that played during the VMAs.

    Here’s the full list of winners:

    Ariana Grande accepts the Video of the Year Award for "Brighter Days Ahead" at Sunday's VMAs.

    Ariana Grande accepts the Video of the Year Award for “Brighter Days Ahead” at Sunday’s VMAs. Image: Manny Carabel/Getty Images

    • Video of the year: Ariana Grande — “brighter days ahead”
    • Artist of the year: Lady Gaga
    • Song of the year: ROSÉ & Bruno Mars — “APT.”
    • Best new artist: Alex Warren
    • Best pop artist: Sabrina Carpenter
    • Best pop: Ariana Grande, “brighter days ahead”
    • Best album: Sabrina Carpenter — “Short n’ Sweet”
    • Best collaboration: Lady Gaga & Bruno Mars — “Die With A Smile”
    • Best hip hop: Doechii — “Anxiety”
    • Best R&B: Mariah Carey — “Type Dangerous”
    • Best country: Megan Moroney, “Am I Okay?”
    • Best K-pop: Lisa ft. Doja Cat & Raye, “Born Again”
    • Best alternative: Sombr, “Back to Friends”
    • Best rock: Coldplay, “All My Love”
    • Best Latin: Shakira, “Soltera”
    • Best Afrobeats: Tyla, “Push 2 Start”
    • MTV Push Performance of the Year: KATSEYE, “Touch”
    • Best long-form video: Ariana Grande — “brighter days ahead”
    • Video for good: Charli xcx — “Guess featuring Billie Eilish”
    • Best direction: Lady Gaga — “Abracadabra”
    • Best art direction: Lady Gaga — “Abracadabra”
    • Best cinematography: Kendrick Lamar — “Not Like Us”
    • Best editing: Tate McRae — “Just Keep Watching (From F1 The Movie)”
    • Best choreography: Doechii — “Anxiety”
    • Best visual effects: Sabrina Carpenter — “Manchild”
    • Song of the summer: Tate McRae — “Just Keep Watching (From F1 The Movie)”
    • Best group: BLACKPINK


    Continue Reading

  • US metals company inks $500m MoU with Pakistan on critical minerals – Firstpost

    US metals company inks $500m MoU with Pakistan on critical minerals – Firstpost

    Acting Deputy Chief of Mission Zach Harkenrider accompanied a USSM-led delegation to the Prime Minister’s House, where the MoU was signed with Pakistan’s Frontier Works Organisation (FWO), according to a report, citing US Embassy

    Pakistan has signed a $500 million memorandum of understanding (MoU) with US-based company US Strategic Metals (USSM), it was revealed on Monday.

    Taking to X, US Embassy Islamabad wrote, “Excited to see U.S. companies like USSM deepening economic ties with Pakistan! USSM’s visit to Islamabad marks an important milestone as they sign an MOU to collaborate on critical minerals production. A forward-looking partnership with great potential for both nations.”

    STORY CONTINUES BELOW THIS AD

    USSM, headquartered in Missouri, specialises in the extraction and recycling of critical minerals, particularly from used lithium-ion batteries, and in the mining of cobalt, nickel, and copper.

    These minerals are classified by the US Department of Energy as vital to advanced manufacturing and energy production technologies.

    According to a Dawn report, citing a press release from the US Embassy, Acting Deputy Chief of Mission Zach Harkenrider accompanied a USSM-led delegation to the Prime Minister’s House, where the MoU was signed with Pakistan’s Frontier Works Organisation (FWO).

    “This signing is yet another example of the strength of the US-Pakistan bilateral relationship that will benefit both countries,” said US Chargé d’Affaires Natalie Baker.

    Baker said that US President Donald Trump’s administration has made forging such deals a key priority, based on the importance of critical mineral resources to American security and prosperity.

    “We look forward to seeing future agreements between US companies and their counterparts in the critical minerals and mining sector in Pakistan,” Baker added.

    A statement from the Prime Minister’s Office said the US Strategic Metals (USSM) delegation is visiting Pakistan to explore opportunities for expanding mining operations and evaluating prospects for value addition in mineral resources, along with the development of related infrastructure.

    STORY CONTINUES BELOW THIS AD

    “[The] delegation held high-level meetings with [the] prime minister of Pakistan, chief of army staff, minister of petroleum and minister of commerce and were briefed on Pakistan’s vast mineral reserves, including copper, gold, and rare earth elements,” The Dawn quoted the statement as saying.

    “In this context, two Memoranda of Understanding, focusing on [the] development and processing of critical minerals, including rare earth elements (REEs), and logistics services, were signed,” added the statement.

    The second MoU was signed between Pakistan’s National Logistics Corporation and Mota-Engil Group, an international engineering and construction company.

    “The current survey of opportunities in Pakistan aims to identify priority markets where Mota-Engil can align with government visions and private sector initiatives. The group seeks to build long-term partnerships that leverage its global know-how while creating value locally through job creation, technology transfer, and sustainable development.”

    According to the statement, the partnership will begin immediately with the export of readily available minerals from Pakistan, including antimony, copper, gold, tungsten, and REEs.

    “The first phase of this deal is envisaged at approximately $500m of investments into Pakistan’s critical minerals sector,” the statement read.

    With inputs from agencies


    Continue Reading

  • Guterres strongly condemns terror attack in Jerusalem – UN News

    1. Guterres strongly condemns terror attack in Jerusalem  UN News
    2. Six killed by Palestinian gunmen at Jerusalem bus stop  BBC
    3. Shooting in occupied East Jerusalem kills six, Israeli authorities say  Al Jazeera
    4. Jerusalem attack terrorists named; IDF chief says he ordered full closure of West Bank villages from which they set out  The Times of Israel
    5. Terror in Jerusalem: Six Israelis murdered, 21 wounded  The Jerusalem Post

    Continue Reading

  • Applovin is soaring. How to tell if the breakout is for real

    Applovin is soaring. How to tell if the breakout is for real

    Continue Reading

  • String of frozen shrimp recalls related to radioactive material may be linked to Indonesia industrial site – SeafoodSource

    1. String of frozen shrimp recalls related to radioactive material may be linked to Indonesia industrial site  SeafoodSource
    2. Indonesian metal facility likely source of radioactive shrimp contamination  Undercurrent News
    3. AI startup Anthropic has agreed to pay $1.5 billion to book authors to settle a copyright suit, marking the largest payout in a U.S. copyright case to date. http://f-st.co/1YbMuv7  LinkedIn
    4. H & N Group Frozen Shrimp Recalled For Radioactivity  Food Poisoning Bulletin
    5. Radioactive shrimp issue will not hinder export to US: Minister  ANTARA News

    Continue Reading